Synova Pre-Natal Healthcare acquires 25% of BioPad, begins testing fetal monitor

By Angela McDaniels

Seattle, Feb. 2 - Synova Pre-Natal Healthcare Inc. has successfully closed on all transaction matters related to its 25% acquisition of BioPad Ltd., according to a company news release.

As part of the acquisition, Synova received exclusive North American distribution rights to a prototype of a fetal monitor developed jointly by the companies.

The device provides a non-invasive means of monitoring fetal movement during the last trimester of pregnancy. Unlike ultrasonic techniques, it does not impart any energy into the mother or her fetus, the company said.

Synova and BioPad have successfully completed initial testing of the device in five subjects and expect to begin U.S. clinical trials later in 2006, according to the release.

"Our vision is to deliver a product that will provide women with added assurance that their fetus is exhibiting normal activity," Synova chief scientific officer Ron Spangler said in the release.

Synova Pre-Natal Healthcare is a Media, Pa.-based subsidiary of Synova Healthcare Group Inc., which distributes over-the-counter medical diagnostics.

BioPad is a research and development organization based in Israel that develops non-invasive medical monitoring devices.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.